EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieOpen Access · CC BY-NC 4.0

LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial

Juying Qian iD, Xuelian Zhang iD, Jiyan Chen iD, Chunhua Ding iD, Ping Yang iD, Li Qing iD, Yan Liu iD, Si Si Chen iD, Junbo Ge iD

Advances in Therapy · 2026

DOI: 10.1007/s12325-025-03429-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, 2026. Verfasst von Juying Qian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Atorvastatin, Ezetimibe, Cholesterol, LDL, Anticholesteremic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Organon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Combining ezetimibe (EZ) and statins is recommended for the treatment of elevated low-density lipoprotein-cholesterol (LDL-C). This subgroup analysis evaluated the efficacy of fixed-dose combination (FDC) therapy with EZ and atorvastatin (AS) versus AS monotherapy on attaining LDL-C goals in Chinese patients with very high risk of atherosclerotic cardiovascular disease (ASCVD) grouped by ASCVD risk, age, and sex. METHODS: Data from the phase III, randomized, double-blind study (NCT03768427) compared EZ10/AS10 mg FDC versus AS20 mg (cohort A), and EZ10/AS20 mg FDC versus AS40 mg monotherapy (cohort B) in Chinese patients with uncontrolled hypercholesterolemia. Proportions of patients attaining 2016 Chinese guideline-recommended LDL-C goals (low/medium risk [< 130 mg/dL], high risk [< 100 mg/dL], very high risk [< 70 mg/dL]) were assessed at weeks 6 and 12. Subgroup analyses by ASCVD risk, age (< 65 and ≥ 65 years), and sex were conducted. RESULTS: LDL-C goal attainment was significantly higher with FDCs versus AS monotherapy at week 12 (cohort A: 62.7% vs. 35.1%, P = 0.0009; cohort B: 67.5% vs. 31.0%, P < 0.0001). A greater proportion of patients with very high ASCVD risk attained LDL-C goals with FDCs versus AS monotherapy at week 12 (cohort A: 62.3% vs. 33.9%; cohort B: 69.1% vs. 29.5%). LDL-C goal attainment was higher with FDCs versus individual doses of AS at weeks 6 and 12 in both cohorts, regardless of age or sex. CONCLUSION: FDCs significantly improved LDL-C goal attainment compared to AS monotherapy in patients with very high ASCVD risk. In the subgroups by age and sex, a higher proportion of patients with uncontrolled hypercholesterolemia attained their LDL-C goals. TRIAL REGISTRY: Trial registration number NCT03768427.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinEzetimibeCholesterol, LDLAnticholesteremic AgentsHypercholesterolemiaHumansFemaleMaleDouble-Blind MethodMiddle AgedAgedChinaDrug Therapy, CombinationDrug Combinations

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseAtorvastatinEzetimibeFixed-dose combinationHypercholesterolemiaLDL-C goal attainmentLipid-lowering therapy

Substanzen

AtorvastatinEzetimibeCholesterol, LDLAnticholesteremic AgentsDrug Combinations

Autor:innen und Institutionen

  • Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Cardiology, Jilin Province People's Hospital, Changchun, Jilin, China.
  • Department of Cardiology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China.
  • Cardiac Department, Aerospace Center Hospital, Beijing, China.
  • Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
  • Medical Affairs, Organon, Chengdu, Sichuan, China.

ORCID-Profile: Juying Qian, Xuelian Zhang, Jiyan Chen, Chunhua Ding, Ping Yang, Li Qing, Yan Liu, Si Si Chen, Junbo Ge

Förderung

  • Organon

Zitieren

APA

Qian, J., Zhang, X., Chen, J., Ding, C., Yang, P., Qing, L., Liu, Y., Chen, S. S., & Ge, J. (2026). LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial. Advances in Therapy. https://doi.org/10.1007/s12325-025-03429-8

Vancouver

Qian J, Zhang X, Chen J, Ding C, Yang P, Qing L, et al. LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial. Advances in Therapy. 2026. doi:10.1007/s12325-025-03429-8

BibTeX
@article{Qian2026,
  author = {Qian, Juying and Zhang, Xuelian and Chen, Jiyan and Ding, Chunhua and Yang, Ping and Qing, Li and Liu, Yan and Chen, Si Si and Ge, Junbo},
  title = {LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial},
  journal = {Advances in Therapy},
  year = {2026},
  doi = {10.1007/s12325-025-03429-8}
}
Kostenlos starten →